Denosumab and clinical outcomes among men with osteoporosis: a retrospective cohort study
Main finding · Hip fractureResult — go to the resultHazard ratio 0.64 95% CI 0.50–0.83Authors' conclusion
In this large, real-world study evaluating denosumab treatment among men with osteoporosis, the observed fracture risk reductions were consistent with the available risk reductions demonstrated in clinical trials among women with postmenopausal osteoporosis.
Study context
- Population
- Men aged ≥ 50 years with osteoporosis who had initiated denosumab in Taiwan248 hip fracture events
- Participants
- 13,797 men
- Exposure
- Denosumab 60 mg subcutaneously every 6 months (on-treatment) vs ending therapy after one administration (off-treatment)
- Outcome
- Hip fracture
Methodological detailspropensity-score inverse probability of treatment weighting, Cox proportional hazards model, Taiwan National Health Insurance Research Database
- Propensity-score inverse probability of treatment weighting
- Cox proportional hazards model
- Taiwan National Health Insurance Research Database
Main finding
As reported in the abstract
Hazard ratio
0.64
95% CI 0.50–0.83
By group
On-treatmentvs Off-treatment
HR 0.64 (95% CI 0.50–0.83)
Observational data: associations, not effects.
Further findings
Clinical vertebral and nonvertebral fractures
- A similar magnitude of risk reduction was observed
Sensitivity analyses, incl. validation with a-million individual health records
- Unmeasured confounders not suggested to impact interpretation
Original publication
Denosumab and clinical outcomes among men with osteoporosis: a retrospective cohort study. Osteoporos Int. Published 8 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →